(2019 / 11 / 06) Q3 of Novo Nordisk 2019: China's market grows by 17%; five ministries and commissions support it! Policy review of the pilot cities of the top 10 clinics; Zhengda Tianqing's fourth generation EGFR-TKI enters the clinical practice to overcome the drug resistance problem of oxitinib; Fosun Pharmaceutical's "spin off" action in further gland Pharma plans to be listed in India Great! It's all big cities There have been many changes Don't send me more bargaining links! Drug resistance is an eternal topic There has been a lot of news in India recently Red envelopes! A lot of growth Quite a lot of money.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![2-(Hydroxymethyl)benzo[b]thiophene](https://file.echemi.com/fileManage/upload/cas/593/e79a972f-b55d-4dc1-9113-841c417e0a89.png)
